Entrada Therapeutics Inc

TRDANASDAQ · USD
5.68USD0.00 (-10.56%)
429

Entrada Therapeutics Inc (TRDA) Covered Calls

As of October 1, 2026, TRDA has 1 covered call opportunities in the coming three months. Return ranges from 30.7 to 30.7% until expiration. Annualized return ranges from 141.9 to 141.9%. The nearest expiration is December 18, 2026. Maximum potential profit is $195.

Read more

Running TRDA covered calls helps you generate consistent income from Entrada Therapeutics Inc's shares you already own, turning a long stock position into a yield-producing asset. A covered call on Entrada Therapeutics Inc involves holding the underlying stock and selling a call option against it, collecting premium in exchange for capping upside at the strike price. Use our scanner to find the best TRDA covered calls in real time and filter for the strikes, expiries, and premiums that fit your strategy.

A covered call is one of the most widely used options strategies because it pairs limited risk with a clear income profile: if TRDA stays below the strike at expiration, you keep the premium and the shares; if it rises above, you deliver the stock at the strike and still pocket the premium. Selling TRDA covered calls works best when implied volatility is elevated, since richer premiums improve the risk-reward. Key inputs to evaluate include strike selection relative to delta, days to expiration, annualized return, and the probability of assignment — all of which determine whether a given Entrada Therapeutics Inc covered call is worth writing.

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc.

in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Income-focused investors, long-term TRDA holders, and systematic premium sellers all face the same challenge: finding the covered call strike and expiry that balances yield against the risk of being called away. Our scanner ranks covered calls by annualized return, downside protection, and probability of profit, so selling TRDA covered calls becomes a measured decision instead of a guess. Stop eyeballing the chain — let the best Entrada Therapeutics Inc covered calls come to you, already filtered for the metrics that matter.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile70.63% Elevated
  • Market cap (M$)221
  • 52 weeks high-65.47%
  • 52 weeks low2.34%
  • Analyst recommendationStrong Buy
    1.29
  • Target price$17.00
    199.30% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-05
  • P/E—
  • Future P/E—
  • EPS (ttm)-3.97
  • EPS growth next 5 years4.81%

As of October 1, 2026

2026-12-18797.5018.110.804.80195.0030.71141.88-12.60+0.70454.00

As of October 1, 2026

Sell covered calls with the data behind you

Find the best TRDA covered call setups ranked by annualized return, filter by premium, delta, and days to expiration, and act on the opportunity in seconds.

Start your 14-day free trial